Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

ClinicalTrials.gov ID: NCT04752332

Public ClinicalTrials.gov record NCT04752332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy

Study identification

NCT ID
NCT04752332
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
111 participants

Conditions and interventions

Interventions

  • Abemaciclib Drug
  • Standard Adjuvant ET Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 9, 2021
Primary completion
Jun 25, 2024
Completion
Jun 25, 2024
Last update posted
Jul 14, 2025

2021 – 2024

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
Palo Verde Cancer Specialists Glendale Arizona 85304
TRIO-US (Translational Research in Oncology-US) Los Angeles California 90024
Millennium Oncology - Hollywood Hollywood Florida 33024
Florida Cancer Specialists - North St. Petersburg Florida 33705
Mt. Sinai Hospital PRiSMS Chicago Illinois 60608
Cornell-Beshore Cancer Institute Joplin Missouri 64804
The Valley Hospital Ridgewood New Jersey 07450
Sarah Cannon Research Institute SCRI Nashville Tennessee 37203
Texas Oncology - Medical City Dallas Dallas Texas 75230
Northwest Cancer Specialists PC The Woodlands Texas 77380
Texas Oncology - Medical City Dallas The Woodlands Texas 77380
US Oncology The Woodlands Texas 77380
USO-Southern Cancer Center, P.C. The Woodlands Texas 77380

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04752332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 14, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04752332 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →